MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $2.56 Million Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 148,638 shares of the biotechnology company’s stock after purchasing an additional 10,047 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of ADMA Biologics worth $2,556,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in ADMA. Perpetual Ltd bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $62,300,000. Allspring Global Investments Holdings LLC raised its stake in shares of ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares in the last quarter. B Group Inc. acquired a new position in shares of ADMA Biologics in the 4th quarter valued at $39,231,000. Raymond James Financial Inc. bought a new position in shares of ADMA Biologics during the 4th quarter worth about $19,076,000. Finally, Arrowstreet Capital Limited Partnership increased its stake in ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock valued at $47,380,000 after acquiring an additional 1,013,456 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $20.44 on Wednesday. The firm’s 50 day moving average is $20.52 and its 200-day moving average is $18.88. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $4.88 billion, a PE ratio of 73.00 and a beta of 0.57. ADMA Biologics, Inc. has a 12-month low of $9.31 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 earnings per share. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. StockNews.com cut ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Finally, Raymond James raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.